Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCs and Scaffold for Dermal Augmentation
NCT05079243Unknown
- Sponsor
- Stemform
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, single-blind trial of autologous adipose-derived stromal cells (Bioheart) in Skin aging and soft tissue defect (2 arms), sponsored by Stemform. Primary endpoint: Volume assessment at 6 months. Status: unknown.
02
Drugs
autologous adipose-derived stromal cells (Bioheart)
03
Conditions
Skin agingsoft tissue defect
Beyond the preview
Go deeper on NCT05079243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079243.